Pharmaceutical Innovation: Is It Really Rewarded?

This publication has been discontinued on December 21, 2011.

Introduction

Abstract

Introduction

Governments in the world' s largest pharmaceutical markets clearly have an interest in promoting access to innovative medicines, but the relatively high price of many novel drugs can place a heavy fi nancial burden on overtaxed health care systems. Thus, the essential challenge for governments and other payers is to strike a balance between the benefi ts and costs of making innovative medicines more widely available.

Get the Answers You Need to Shape Your Strategy

• The European Commission wants to balance strict price controls and free market pricing. What initiatives has the EU undertaken to achieve this balance? Which EU markets have the strictest constraints on pharmaceutical pricing? Are new policies likely to improve or worsen the climate for pharmaceutical companies?
• Recently, the Japanese government has taken action intended to make premiums for innovation more generous and more attainable. What price reforms has the government made? Are they likely to in fact encourage innovation? Will the new price premiums be achievable?
• In the United States, the increasing focus on drug prices will prompt more payers to adopt evidence-based formularies. How is formulary decision making evolving in the private sector? How is Medicare now encouraging health economic research?

Scope

• EU innovation initiatives: a review of recent initiatives by the EU in support of innovative medicines in Europe.
• Outlook and implications for the pharmaceutical industry: the future of reimbursement for innovative drugs in the EU, Japan, and the United States.
• Detailed analysis of pricing and reimbursement in the major markets: an examination of how health care payers in seven leading pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom, Japan, and United States) approach the pricing and reimbursement of innovative drugs.

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Innovation: Balancing Benefi ts and Costs
• European Union
  • High-Level Group on Innovation and the Provision of Medicines (G10 Medicines Group)
  • High-Level Pharmaceutical Forum
• France
  • Standard Price-Setting Procedure
  • Price Setting for Innovative Drugs
  • Renewal of Pricing and Reimbursement
• Germany
  • Reference Pricing
  • Prescribing Budgets
  • Health Technology Assessment
  • New Restrictions on the Use of Costly Drugs
• Italy
• Spain
  • Price Setting
  • Prior Authorization
  • More Selective Funding of Medicines
• United Kingdom
  • Proposal to Replace the Pharmaceutical Price Regulation Scheme
  • National Institute for Clinical Excellence
    • Review of Variations in the Use of NICE-Approved Cancer Drugs
    • Patient Action Against Lack of Access to Certain Drugs
    • Accelerated NICE Appraisal Process
• Japan
  • Initial Pricing of Branded Prescription Drugs
    • Similar-Effi cacy Comparison Methods
    • Cost Calculation Method
    • Price Premiums
• United States
  • Formulary Decision Making in the Private Sector
  • Medicare Sponsorship of Health Economic Research
• Outlook and Implications for the Pharmaceutical Industry

Tables:

• 1. Methods Used for Pricing New Drugs in Japan, June 2002-March 2007
• 2. Hierarchy of National Health Insurance Price Premiums in Japan
• 3. Number of New Drugs Awarded Price Premiums for Therapeutic Advances, June 2002-March 2007
• 4. U.S. Employers' Views on Strategies to Increase Prescription Drug Benefit Value
• 5. U.S. Employers' Views on Strategies to Increase Prescription Drug Benefit Value

Figures:

• 1. New Drugs' Share of Total Pharmaceutical Expenditures in Major Markets, 2001-2004
• 2. Percentage of Drugs Awarded Various SMR Ratings in France
• 3. Percentage of Drugs Awarded Various ASMR Ratings in France
• 4. Criteria for Determining the Pricing Method Used for New Prescription Drugs in Japan

Related Reports